Twilight will offer technical know-how against 26% of fully paid equity shares of Interpro Healthcare, the company said in a filing to the Bombay Stock Exchange.
Interpro will be required to buy the products exclusively from Twilight which will be registered and marketed by Interpro Healthcare in South Africa.
The deal is expected to enable Twilight to foray into the South African pharma market.
Twilight manufactures drugs and formulations related to analgesics, antibiotics, anti-bacterials, vitamins and cardialogy in the form of tablets, capsules, ointment and liquids.